SenesTech Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Joel Fruendt

Algemeen directeur

US$458.3k

Totale compensatie

Percentage CEO-salaris	9.6%
Dienstverband CEO	1.3yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Joel Fruendt's beloning veranderd ten opzichte van SenesTech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$458k	US$44k	-US$10m

Compensatie versus markt: De totale vergoeding ($USD 458.33K ) Joel } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 476.59K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Joel te vergelijken met de prestaties van het bedrijf.

CEO

Joel Fruendt (62 yo)

1.3yrs

Tenure

US$458,331

Compensatie

Mr. Joel L. Fruendt serves as Chief Executive Officer and Director of SenesTech, Inc. since November 15, 2022. He serves as President at SenesTech, Inc. since December 2022. Most recently he served as Pres...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joel Fruendt	CEO, President & Director	1.3yrs	US$458.33k	0.023% € 1.2k
Anders Field	Advisor	no data	geen gegevens	geen gegevens
Matthew Szot	Independent Vice-Chairman of the Board	8.2yrs	US$120.00k	0.00042% € 22.2
Jacob Leach	Independent Director	3.3yrs	US$60.00k	0.013% € 690.7
Julia Williams	Director Emeritus	3.3yrs	US$49.63k	0% € 0
Bill Calloway	Advisor	no data	geen gegevens	geen gegevens
Jamie Bechtel	Independent Chairman of the Board & Lead Independent Director	6.1yrs	US$180.70k	0.00025% € 13.2
Delphine Chiavarini	Independent Director	5.7yrs	US$78.50k	0.00013% € 6.9
Phil Grandinetti	Independent Director	3.3yrs	US$76.00k	0% € 0

3.3yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SE81 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

SenesTech Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

SenesTech, Inc., Annual General Meeting, Jul 11, 2024

Senestech Names Nicole Williams as Chief Revenue Officer

SenesTech, Inc. Announces Executive Changes

SenesTech Announces Resignation of K.C. Kavanagh as Member of Board of Directors

SenesTech, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Recent updates

SenesTech Launches Evolve Rodent Birth Control on Walmart Marketplace

SenesTech, Inc. to Report Q3, 2024 Results on Nov 12, 2024

SenesTech, Inc.'s Evolve™ Registers in Hong Kong; Offering a Revolutionary Non-Lethal Rodent Control Solution

SenesTech Receives Notification from Nasdaq Due to Non-Compliance with Nasdaq’s Audit Committee Requirements as Set Forth in Nasdaq Listing Rule 5605

SenesTech, Inc. to Report Q2, 2024 Results on Aug 08, 2024

SenesTech, Inc. has filed a Follow-on Equity Offering in the amount of $1.575944 million.

SenesTech, Inc., Annual General Meeting, Jul 11, 2024

SenesTech, Inc. to Report Q1, 2024 Results on May 09, 2024

Nasdaq Determines SenesTech Eligible for an Additional 180 Calendar Day Period, or Until August 19, 2024, to Regain Compliance with the Minimum Bid Price Requirement

SenesTech, Inc. to Report Q4, 2023 Results on Feb 21, 2024

SenesTech Partners with Global Leader in Irrigation Solutions to Expand Evolve Soft Bait to Open Field Agriculture Applications

SenesTech's ContraPest Registered for Use in Puerto Rico to Combat Rat Infestations

SenesTech, Inc. has completed a Follow-on Equity Offering.

SenesTech, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

SenesTech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Third quarter 2023 earnings released: US$0.47 loss per share (vs US$4.33 loss in 3Q 2022)

SenesTech, Inc. to Report Q3, 2023 Results on Nov 09, 2023

SenesTech Taking Orders for Evolve™ Soft Bait for Rodent Fertility Control

SenesTech, Inc. Launches Evolve Soft Bait for Rodent Fertility Control

SenesTech Receives Non-Compliance Letter from Nasdaq

Second quarter 2023 earnings released: US$0.70 loss per share (vs US$4.21 loss in 2Q 2022)

SenesTech, Inc. to Report Q2, 2023 Results on Aug 10, 2023

SenesTech, Inc. Launches Isolate Bait System for Contrapest

First quarter 2023 earnings released: US$0.001 loss per share (vs US$3.82 loss in 1Q 2022)

SenesTech, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Senestech Names Nicole Williams as Chief Revenue Officer

Third quarter 2022 earnings released: US$0.22 loss per share (vs US$0.18 loss in 3Q 2021)

SenesTech, Inc. Announces Executive Changes

SenesTech, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SenesTech Announces Resignation of K.C. Kavanagh as Member of Board of Directors

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.14 loss in 2Q 2021)

SenesTech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

SenesTech, Inc. Announces its New Elevate Bait System with ContraPest Now Available in California

SenesTech, Inc. Announces its New Elevate Bait System with ContraPest Available for Sale

First quarter 2022 earnings released: US$0.19 loss per share (vs US$0.22 loss in 1Q 2021)

SenesTech, Inc. to Report Q1, 2022 Results on May 12, 2022

SenesTech, Inc., Annual General Meeting, Jun 23, 2022

Full year 2021 earnings released: US$0.74 loss per share (vs US$2.79 loss in FY 2020)

High number of new directors

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.56 loss in 3Q 2020)

Independent Director recently bought €195k worth of stock

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.59 loss in 2Q 2020)

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.22 loss per share (vs US$1.70 loss in 1Q 2020)

Full year 2020 earnings released: US$2.64 loss per share (vs US$7.69 loss in FY 2019)